StockData
Kalaris Therapeutics, Inc. logo

Kalaris Therapeutics, Inc. (KLRS) stock

KLRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.43−0.03 (-2.05%)

Close on Nov 17, 2026Market cap $34.04MP/E –Yield –

Earnings

Kalaris Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 16, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.46
-$0.64 a year earlier
Latest guidance
Reaffirmed
Aug 3, 2023 · 1 item

Quarterly results

Revenue and earnings per share from each of Kalaris Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 16, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 10, 2026before the open––-$0.46Release
Q2 FY2026ended Jun 30, 2026Aug 11, 2026before the open–––Release
Q1 FY2026ended Mar 31, 2026May 12, 2026before the open––-$0.46Release
Q4 FY2025ended Dec 31, 2025Mar 17, 2026before the open–––Release
Q3 FY2025ended Sep 30, 2025Nov 12, 2025before the open––-$0.64Release
Q2 FY2025ended Jun 30, 2025Aug 13, 2025before the open––-$0.61Release
Q1 FY2025ended Mar 31, 2025May 14, 2025before the open––-$2.52Release
Q4 FY2024ended Dec 31, 2024Mar 18, 2025during market hours–––Release
Q3 FY2023ended Sep 30, 2023Nov 2, 2023before the open–––Release
Q2 FY2023ended Jun 30, 2023Aug 3, 2023before the open––-$0.48Release
Q1 FY2023ended Mar 31, 2023May 4, 2023before the open––-$0.44Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period Kalaris Therapeutics guided for has been reported

Guidance history

Every forecast Kalaris Therapeutics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 3, 2023operating expensesFY2023$150.00M – $170.00MReaffirmed
Feb 15, 2023operating expensesFY2023$150.00M – $170.00MNew
Nov 3, 2022operating expensesFY2022$130.00M – $145.00MReaffirmed
Aug 4, 2022operating expensesFY2022$130.00M – $145.00MReaffirmed
Feb 10, 2022operating expensesFY2022$130.00M – $145.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Kalaris Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Update
  4. Update
  5. Results
  6. Results
  7. Update
  8. News
  9. Update
  10. Update
  11. Results
  12. Results
  13. Results
  14. Results
  15. Results

See a number that looks wrong?